Double-Blind, Randomized, Placebo and Alprazolam-Controlled Three-Period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-Like fMRI Activity of GW876008 and GSK561679 After Single-Dose Administration in Subjects With Social Anxiety Disorder (SAD).

Trial Profile

Double-Blind, Randomized, Placebo and Alprazolam-Controlled Three-Period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-Like fMRI Activity of GW876008 and GSK561679 After Single-Dose Administration in Subjects With Social Anxiety Disorder (SAD).

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Emicerfont (Primary) ; Verucerfont (Primary) ; Alprazolam
  • Indications Social phobia
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 Oct 2012 Additional information source identified and integrated European Clinical Trials database record EudraCT2006-004212-48
    • 15 Oct 2008 Actual start date changed from Feb 2007 to Mar 2007 as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top